Table 3 A comparison of outcomes of this study with other prospective clinical trials
Number of patients | RR (%) | Median PFS (weeks) | PFS-6 (%) | Median OS (weeks) | Reference | Regimen |
|---|---|---|---|---|---|---|
Grade 3 | ||||||
32 | 24 | 24 (16–33) | 41 (24,57) | 63.1 (36–∞) | Current study | BV + etoposide |
33 | 61 | 30 (21–60) | 55 (36–70) | 65 (32–99) | BV + CPT-11 | |
GBM | ||||||
27 | 23 | 18 (13–40) | 44.4 (26–62) | 46.4 (25–70) | Current study | BV + etoposide |
35 | 57 | 24 (18–36) | 46 (32–66) | 42 (35–60) | 7 | |
85 | 28 | 17 (12–23) | 43 (30–56) | 36.8 (33–43) | BV monotherapy | |
82 | 38 | 22 (18–25) | 50 (37–64) | 34.8 (31–44) | BV + CPT-11 | |
48 | 35 | 16 (12–26) | 29 (18–48) | 31 (21–54) | BV monotherapy | |
